117 related articles for article (PubMed ID: 9848381)
1. Malignant hyperthermia.
Bouchama A; Hussain S
Lancet; 1998 Nov; 352(9142):1785. PubMed ID: 9848381
[No Abstract] [Full Text] [Related]
2. Malignant hyperthermia and apparent heat stroke.
Tobin JR; Jason DR; Challa VR; Nelson TE; Sambuughin N
JAMA; 2001 Jul; 286(2):168-9. PubMed ID: 11448278
[No Abstract] [Full Text] [Related]
3. Identification of variants of the ryanodine receptor type 1 in patients with exertional heat stroke and positive response to the malignant hyperthermia in vitro contracture test.
Roux-Buisson N; Monnier N; Sagui E; Abriat A; Brosset C; Bendahan D; Kozak-Ribbens G; Gazzola S; Quesada JL; Foutrier-Morello C; Rendu J; Figarella-Branger D; Cozonne P; Aubert M; Bourdon L; Lunardi J; Fauré J
Br J Anaesth; 2016 Apr; 116(4):566-8. PubMed ID: 26994242
[No Abstract] [Full Text] [Related]
4. Exertional Heat Stroke and Susceptibility to Malignant Hyperthermia in an Athlete: Evidence for a Link?
Poussel M; Guerci P; Kaminsky P; Heymonet M; Roux-Buisson N; Faure J; Fronzaroli E; Chenuel B
J Athl Train; 2015 Nov; 50(11):1212-4. PubMed ID: 26565425
[TBL] [Abstract][Full Text] [Related]
5. Central core disease and susceptibility to malignant hyperthermia in a single family.
Colleoni L; Melli G; Morandi L; Cudia P; Romaggi S; Mantegazza R; Bernasconi P
J Neurol; 2009 Jul; 256(7):1161-3. PubMed ID: 19252784
[No Abstract] [Full Text] [Related]
6. Malignant hyperthermia: a pharmacogenetic disorder.
Stratman RC; Flynn JD; Hatton KW
Orthopedics; 2009 Nov; 32(11):835. PubMed ID: 19902883
[No Abstract] [Full Text] [Related]
7. PharmGKB summary: very important pharmacogene information for RYR1.
Alvarellos ML; Krauss RM; Wilke RA; Altman RB; Klein TE
Pharmacogenet Genomics; 2016 Mar; 26(3):138-44. PubMed ID: 26709912
[No Abstract] [Full Text] [Related]
8. [Malignant hyperthermia as a complication of anesthesia: predisposition is hereditary].
Snoeck MM; Gielen MJ; Sengers RC; Padberg GW; Iles DE; Booij LH
Ned Tijdschr Geneeskd; 1997 Mar; 141(13):616-9. PubMed ID: 9190536
[TBL] [Abstract][Full Text] [Related]
9. Effects of ryanodine on skeletal muscle lactate and pyruvate in malignant hyperthermia-susceptible and normal swine as assessed by microdialysis.
Bina S; Muldoon S; Bünger R
Eur J Anaesthesiol; 2008 Jan; 25(1):48-57. PubMed ID: 17686208
[TBL] [Abstract][Full Text] [Related]
10. Identification of a novel mutation in the ryanodine receptor gene (RYR1) in a malignant hyperthermia Italian family.
Fortunato G; Berruti R; Brancadoro V; Fattore M; Salvatore F; Carsana A
Eur J Hum Genet; 2000 Feb; 8(2):149-52. PubMed ID: 10757649
[TBL] [Abstract][Full Text] [Related]
11. A study of a family with the skeletal muscle RYR1 mutation (c.7354C>T) associated with central core myopathy and malignant hyperthermia susceptibility.
Taylor A; Lachlan K; Manners RM; Lotery AJ
J Clin Neurosci; 2012 Jan; 19(1):65-70. PubMed ID: 22030266
[TBL] [Abstract][Full Text] [Related]
12. Malignant hyperthermia: a pharmacogenetic disorder.
Stowell KM
Pharmacogenomics; 2008 Nov; 9(11):1657-72. PubMed ID: 19018722
[TBL] [Abstract][Full Text] [Related]
13. Functional studies of RYR1 mutations in the skeletal muscle ryanodine receptor using human RYR1 complementary DNA.
Sato K; Pollock N; Stowell KM
Anesthesiology; 2010 Jun; 112(6):1350-4. PubMed ID: 20461000
[TBL] [Abstract][Full Text] [Related]
14. Evidence for a spontaneous C1840-T mutation in the RYR1 gene after DNA fingerprinting in a malignant hyperthermia susceptible family.
Steinfath M; Seranski P; Singh S; Fiege M; Wappler F; Schulte Am Esch J; Scholz J
Naunyn Schmiedebergs Arch Pharmacol; 2002 Oct; 366(4):372-5. PubMed ID: 12237752
[TBL] [Abstract][Full Text] [Related]
15. Myopathic changes in malignant hyperthermia-susceptible patients.
Rosenberg H
Can J Anaesth; 2013 Oct; 60(10):955-9. PubMed ID: 23897489
[No Abstract] [Full Text] [Related]
16. Heat- and anesthesia-induced malignant hyperthermia in an RyR1 knock-in mouse.
Chelu MG; Goonasekera SA; Durham WJ; Tang W; Lueck JD; Riehl J; Pessah IN; Zhang P; Bhattacharjee MB; Dirksen RT; Hamilton SL
FASEB J; 2006 Feb; 20(2):329-30. PubMed ID: 16284304
[TBL] [Abstract][Full Text] [Related]
17. [Biology of malignant hyperthermia: a disease of the calcium channels of the skeletal muscle].
Monnier N; Lunardi J
Ann Biol Clin (Paris); 2000; 58(2):147-56. PubMed ID: 10760701
[TBL] [Abstract][Full Text] [Related]
18. The genetics of malignant hyperthermia.
Brandom BW
Anesthesiol Clin North Am; 2005 Dec; 23(4):615-9, viii. PubMed ID: 16310654
[TBL] [Abstract][Full Text] [Related]
19. Core myopathies and risk of malignant hyperthermia.
Klingler W; Rueffert H; Lehmann-Horn F; Girard T; Hopkins PM
Anesth Analg; 2009 Oct; 109(4):1167-73. PubMed ID: 19762745
[TBL] [Abstract][Full Text] [Related]
20. Ryanodine receptor mutations in malignant hyperthermia and central core disease.
McCarthy TV; Quane KA; Lynch PJ
Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
